Clinical Trials
Multiple clinical trials evaluate the diagnostic utility of iothalamate sodium clearance for measuring glomerular filtration rates and renal functional reserve in conditions including kidney donation, kidney failure, renal transplantation, chronic kidney disease, and liver failure with renal impairment. Sponsored by academic institutions, medical centers, and government bodies such as the National Institute of Allergy and Infectious Diseases, Stanford University, and Brigham and Women's Hospital, these studies encompass both completed trials and those with unknown recruitment status. Across this portfolio, trial phases are designated as either unprovided or not applicable.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06259422 | UNKNOWN | Kidney Function Issue; Diagnosis; Chronic Kidney Diseases |
University Medical Center Groningen |
2024-06-01 | |
| NCT03190070 | COMPLETED | Kidney Diseases |
Brigham and Women's Hospital |
2017-07-12 |
(data from https://clinicaltrials.gov, updated on 2024-03-13)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).